The comparitive analysis of the ebaf protein levels in this variety of patients will help set the standards for the Lexon test kit. Prior to joining CIS, Mr. Mabie was with Honeywell Information Systems, Inc., where he ranked as one of its top five salesmen worldwide. He holds degrees in accounting and economics from Memphis State University and served for eight years in the United States Navy. The Ebaf Assay Test Lexon's Medical Director, Thomas Coughlin, M.D., has written an article to explain the importance of this test. We have reprinted excerpts to help our readers understand how valuable this test is.
Colon cancer is the second leading cause of cancer deaths in the United States.
About 173,000 cases of colon and rectal cancer are diagnosed every year in the U.S., resulting in a death rate of approximately 80,000 per year. 900,000 of those cases are colorectal cancer. However, colon cancer is easily treated. When the Lexon Ebaf Assay test becomes available, any hospital laboratory will be able to test the blood of patients for the presence of the colon cancer marker. A positive test will alert the patient's physician.